Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies

[Display omitted] •Novel berberine hyalurosomes nanogel as nanodermatological treatment for vitiligo.•Hyalurosomes mimic the skin structure so it enhances berberine poor permeability.•Berberine hyalurosomes showed significant increase in berberine skin deposition.•Berberine hyalurosomes presented su...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2022-03, Vol.615, p.121523-121523, Article 121523
Hauptverfasser: Elhalmoushy, Passant M., Elsheikh, Manal A, Matar, Noura A., El-Hadidy, Wessam F., Kamel, Maher A, Omran, Gamal A., Elnaggar, Yosra S.R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 121523
container_issue
container_start_page 121523
container_title International journal of pharmaceutics
container_volume 615
creator Elhalmoushy, Passant M.
Elsheikh, Manal A
Matar, Noura A.
El-Hadidy, Wessam F.
Kamel, Maher A
Omran, Gamal A.
Elnaggar, Yosra S.R.
description [Display omitted] •Novel berberine hyalurosomes nanogel as nanodermatological treatment for vitiligo.•Hyalurosomes mimic the skin structure so it enhances berberine poor permeability.•Berberine hyalurosomes showed significant increase in berberine skin deposition.•Berberine hyalurosomes presented successful restoration of normal skin color.•Biochemical studies confirm berberine hyalurosomes efficacy and safety. Vitiligo is a depigmentation disorder that affects 0.5–2% of the world population. It has a severe impact on a patient's quality of life and even causes suicidal attempts. Up to date, no curative therapy is available which have created a substantial demand for novel vitiligo treatments. Berberine (BRB) is an isoquinoline alkaloid with promising pharmacological effects. However, it suffers from poor membrane permeability hindering its topical application. The current work is the first to design and assess topical BRB-loaded hyalurosomes for targeted vitiligo treatment. BRB-hyalurosomes are hyaluronan-immobilized phospholipid nanovesicles that showed promising invitro physicochemical properties. Novel ex vivo studies were performed using full-thickness human skin to mimic its dermal application. Furthermore, in-vivo studies were conducted using a vitiligo-induced mouse model followed by biochemical, histological and immunohistochemical investigations. In addition, gene expression of skin inflammatory markers was assessed using quantitative reverse-transcription PCR. Biological studies showed significant improvement of the biochemical markers in BRB-hyalurosomes group compared to the vitiligo-model group and BRB conventional gel. It is worthy to mention that placebo hyalurosomes demonstrated significant enhancement in the biological activity confirming its intrinsic activity. Conclusively, BRB-hyalurosomes is considered a novel nanodermatological tool that paving the way for its clinical application for vitiligo treatment.
doi_str_mv 10.1016/j.ijpharm.2022.121523
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2624951604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517322000771</els_id><sourcerecordid>2624951604</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-205591f5a7c77d84b28929d4745cead2cf5c66b9786808808084fba1dfdcf9333</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS1ERUPhEUBesmBS_4w9M2xQqfiTqnYDa8tj30kceexgeyL6GLwxjhK6RTrS3Xz3Xp1zEHpDyZoSKq93a7fbb3Wa14wwtqaMCsafoRXtO97wtpPP0Yrwrm8E7fglepnzjhAiGeUv0CUXlLRikCv05z4ewOMRUpUL0PioLVi8fdR-STHHGTLWVXif4uyyCxscdIgW0qxL9HHjjPa4JNBlhlDwFBM-uOK828QP-JOLZgvzkXmPR_fE62DxBgJg-L1PkLOLAeeyWAf5FbqYtM_w-jyv0M8vn3_cfmvuHr5-v725awyXojSMCDHQSejOdJ3t25H1Axts27XCgLbMTMJIOQ5dL3vSV5G-nUZN7WTNNHDOr9C7091q7NcCuahqz4D3OkBcsmKStYOgkrQVFSfU1ERygkntk5t1elSUqGMbaqfObahjG-rURt17e36xjDPYp61_8Vfg4wmAavTgIKlsHAQD1iUwRdno_vPiLyrRoW4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2624951604</pqid></control><display><type>article</type><title>Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Elhalmoushy, Passant M. ; Elsheikh, Manal A ; Matar, Noura A. ; El-Hadidy, Wessam F. ; Kamel, Maher A ; Omran, Gamal A. ; Elnaggar, Yosra S.R.</creator><creatorcontrib>Elhalmoushy, Passant M. ; Elsheikh, Manal A ; Matar, Noura A. ; El-Hadidy, Wessam F. ; Kamel, Maher A ; Omran, Gamal A. ; Elnaggar, Yosra S.R.</creatorcontrib><description>[Display omitted] •Novel berberine hyalurosomes nanogel as nanodermatological treatment for vitiligo.•Hyalurosomes mimic the skin structure so it enhances berberine poor permeability.•Berberine hyalurosomes showed significant increase in berberine skin deposition.•Berberine hyalurosomes presented successful restoration of normal skin color.•Biochemical studies confirm berberine hyalurosomes efficacy and safety. Vitiligo is a depigmentation disorder that affects 0.5–2% of the world population. It has a severe impact on a patient's quality of life and even causes suicidal attempts. Up to date, no curative therapy is available which have created a substantial demand for novel vitiligo treatments. Berberine (BRB) is an isoquinoline alkaloid with promising pharmacological effects. However, it suffers from poor membrane permeability hindering its topical application. The current work is the first to design and assess topical BRB-loaded hyalurosomes for targeted vitiligo treatment. BRB-hyalurosomes are hyaluronan-immobilized phospholipid nanovesicles that showed promising invitro physicochemical properties. Novel ex vivo studies were performed using full-thickness human skin to mimic its dermal application. Furthermore, in-vivo studies were conducted using a vitiligo-induced mouse model followed by biochemical, histological and immunohistochemical investigations. In addition, gene expression of skin inflammatory markers was assessed using quantitative reverse-transcription PCR. Biological studies showed significant improvement of the biochemical markers in BRB-hyalurosomes group compared to the vitiligo-model group and BRB conventional gel. It is worthy to mention that placebo hyalurosomes demonstrated significant enhancement in the biological activity confirming its intrinsic activity. Conclusively, BRB-hyalurosomes is considered a novel nanodermatological tool that paving the way for its clinical application for vitiligo treatment.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2022.121523</identifier><identifier>PMID: 35104596</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Berberine ; Gene Expression ; Hyalurosomes ; Hydroquinone ; Mice ; Mouse model ; Nanodermatology ; Quality of Life ; Skin ; Vitiligo ; Vitiligo - drug therapy</subject><ispartof>International journal of pharmaceutics, 2022-03, Vol.615, p.121523-121523, Article 121523</ispartof><rights>2022 Elsevier B.V.</rights><rights>Copyright © 2022 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-205591f5a7c77d84b28929d4745cead2cf5c66b9786808808084fba1dfdcf9333</citedby><cites>FETCH-LOGICAL-c365t-205591f5a7c77d84b28929d4745cead2cf5c66b9786808808084fba1dfdcf9333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378517322000771$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35104596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Elhalmoushy, Passant M.</creatorcontrib><creatorcontrib>Elsheikh, Manal A</creatorcontrib><creatorcontrib>Matar, Noura A.</creatorcontrib><creatorcontrib>El-Hadidy, Wessam F.</creatorcontrib><creatorcontrib>Kamel, Maher A</creatorcontrib><creatorcontrib>Omran, Gamal A.</creatorcontrib><creatorcontrib>Elnaggar, Yosra S.R.</creatorcontrib><title>Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] •Novel berberine hyalurosomes nanogel as nanodermatological treatment for vitiligo.•Hyalurosomes mimic the skin structure so it enhances berberine poor permeability.•Berberine hyalurosomes showed significant increase in berberine skin deposition.•Berberine hyalurosomes presented successful restoration of normal skin color.•Biochemical studies confirm berberine hyalurosomes efficacy and safety. Vitiligo is a depigmentation disorder that affects 0.5–2% of the world population. It has a severe impact on a patient's quality of life and even causes suicidal attempts. Up to date, no curative therapy is available which have created a substantial demand for novel vitiligo treatments. Berberine (BRB) is an isoquinoline alkaloid with promising pharmacological effects. However, it suffers from poor membrane permeability hindering its topical application. The current work is the first to design and assess topical BRB-loaded hyalurosomes for targeted vitiligo treatment. BRB-hyalurosomes are hyaluronan-immobilized phospholipid nanovesicles that showed promising invitro physicochemical properties. Novel ex vivo studies were performed using full-thickness human skin to mimic its dermal application. Furthermore, in-vivo studies were conducted using a vitiligo-induced mouse model followed by biochemical, histological and immunohistochemical investigations. In addition, gene expression of skin inflammatory markers was assessed using quantitative reverse-transcription PCR. Biological studies showed significant improvement of the biochemical markers in BRB-hyalurosomes group compared to the vitiligo-model group and BRB conventional gel. It is worthy to mention that placebo hyalurosomes demonstrated significant enhancement in the biological activity confirming its intrinsic activity. Conclusively, BRB-hyalurosomes is considered a novel nanodermatological tool that paving the way for its clinical application for vitiligo treatment.</description><subject>Animals</subject><subject>Berberine</subject><subject>Gene Expression</subject><subject>Hyalurosomes</subject><subject>Hydroquinone</subject><subject>Mice</subject><subject>Mouse model</subject><subject>Nanodermatology</subject><subject>Quality of Life</subject><subject>Skin</subject><subject>Vitiligo</subject><subject>Vitiligo - drug therapy</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uEzEUhS1ERUPhEUBesmBS_4w9M2xQqfiTqnYDa8tj30kceexgeyL6GLwxjhK6RTrS3Xz3Xp1zEHpDyZoSKq93a7fbb3Wa14wwtqaMCsafoRXtO97wtpPP0Yrwrm8E7fglepnzjhAiGeUv0CUXlLRikCv05z4ewOMRUpUL0PioLVi8fdR-STHHGTLWVXif4uyyCxscdIgW0qxL9HHjjPa4JNBlhlDwFBM-uOK828QP-JOLZgvzkXmPR_fE62DxBgJg-L1PkLOLAeeyWAf5FbqYtM_w-jyv0M8vn3_cfmvuHr5-v725awyXojSMCDHQSejOdJ3t25H1Axts27XCgLbMTMJIOQ5dL3vSV5G-nUZN7WTNNHDOr9C7091q7NcCuahqz4D3OkBcsmKStYOgkrQVFSfU1ERygkntk5t1elSUqGMbaqfObahjG-rURt17e36xjDPYp61_8Vfg4wmAavTgIKlsHAQD1iUwRdno_vPiLyrRoW4</recordid><startdate>20220305</startdate><enddate>20220305</enddate><creator>Elhalmoushy, Passant M.</creator><creator>Elsheikh, Manal A</creator><creator>Matar, Noura A.</creator><creator>El-Hadidy, Wessam F.</creator><creator>Kamel, Maher A</creator><creator>Omran, Gamal A.</creator><creator>Elnaggar, Yosra S.R.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220305</creationdate><title>Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies</title><author>Elhalmoushy, Passant M. ; Elsheikh, Manal A ; Matar, Noura A. ; El-Hadidy, Wessam F. ; Kamel, Maher A ; Omran, Gamal A. ; Elnaggar, Yosra S.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-205591f5a7c77d84b28929d4745cead2cf5c66b9786808808084fba1dfdcf9333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Berberine</topic><topic>Gene Expression</topic><topic>Hyalurosomes</topic><topic>Hydroquinone</topic><topic>Mice</topic><topic>Mouse model</topic><topic>Nanodermatology</topic><topic>Quality of Life</topic><topic>Skin</topic><topic>Vitiligo</topic><topic>Vitiligo - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Elhalmoushy, Passant M.</creatorcontrib><creatorcontrib>Elsheikh, Manal A</creatorcontrib><creatorcontrib>Matar, Noura A.</creatorcontrib><creatorcontrib>El-Hadidy, Wessam F.</creatorcontrib><creatorcontrib>Kamel, Maher A</creatorcontrib><creatorcontrib>Omran, Gamal A.</creatorcontrib><creatorcontrib>Elnaggar, Yosra S.R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elhalmoushy, Passant M.</au><au>Elsheikh, Manal A</au><au>Matar, Noura A.</au><au>El-Hadidy, Wessam F.</au><au>Kamel, Maher A</au><au>Omran, Gamal A.</au><au>Elnaggar, Yosra S.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2022-03-05</date><risdate>2022</risdate><volume>615</volume><spage>121523</spage><epage>121523</epage><pages>121523-121523</pages><artnum>121523</artnum><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] •Novel berberine hyalurosomes nanogel as nanodermatological treatment for vitiligo.•Hyalurosomes mimic the skin structure so it enhances berberine poor permeability.•Berberine hyalurosomes showed significant increase in berberine skin deposition.•Berberine hyalurosomes presented successful restoration of normal skin color.•Biochemical studies confirm berberine hyalurosomes efficacy and safety. Vitiligo is a depigmentation disorder that affects 0.5–2% of the world population. It has a severe impact on a patient's quality of life and even causes suicidal attempts. Up to date, no curative therapy is available which have created a substantial demand for novel vitiligo treatments. Berberine (BRB) is an isoquinoline alkaloid with promising pharmacological effects. However, it suffers from poor membrane permeability hindering its topical application. The current work is the first to design and assess topical BRB-loaded hyalurosomes for targeted vitiligo treatment. BRB-hyalurosomes are hyaluronan-immobilized phospholipid nanovesicles that showed promising invitro physicochemical properties. Novel ex vivo studies were performed using full-thickness human skin to mimic its dermal application. Furthermore, in-vivo studies were conducted using a vitiligo-induced mouse model followed by biochemical, histological and immunohistochemical investigations. In addition, gene expression of skin inflammatory markers was assessed using quantitative reverse-transcription PCR. Biological studies showed significant improvement of the biochemical markers in BRB-hyalurosomes group compared to the vitiligo-model group and BRB conventional gel. It is worthy to mention that placebo hyalurosomes demonstrated significant enhancement in the biological activity confirming its intrinsic activity. Conclusively, BRB-hyalurosomes is considered a novel nanodermatological tool that paving the way for its clinical application for vitiligo treatment.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>35104596</pmid><doi>10.1016/j.ijpharm.2022.121523</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2022-03, Vol.615, p.121523-121523, Article 121523
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_2624951604
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Berberine
Gene Expression
Hyalurosomes
Hydroquinone
Mice
Mouse model
Nanodermatology
Quality of Life
Skin
Vitiligo
Vitiligo - drug therapy
title Novel berberine-loaded hyalurosomes as a promising nanodermatological treatment for vitiligo: Biochemical, biological and gene expression studies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T17%3A37%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20berberine-loaded%20hyalurosomes%20as%20a%20promising%20nanodermatological%20treatment%20for%20vitiligo:%20Biochemical,%20biological%20and%20gene%20expression%20studies&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Elhalmoushy,%20Passant%20M.&rft.date=2022-03-05&rft.volume=615&rft.spage=121523&rft.epage=121523&rft.pages=121523-121523&rft.artnum=121523&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2022.121523&rft_dat=%3Cproquest_cross%3E2624951604%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2624951604&rft_id=info:pmid/35104596&rft_els_id=S0378517322000771&rfr_iscdi=true